スマートピル市場は、2024年の6億9000万ドルから2030年までに13億ドルに成長し、予測期間中のCAGRは11.2%になると予想されます。スマートピル市場で活動している主要企業には、Medtronic(米国)、オリンパス株式会社 (日本)、CapsoVision,Inc.(米国)、IntroMedic(韓国)、ANX Robotics(米国)、Shenzhen Jifu Medical Technology Co., Ltd.(中国)、JINSHAN Science & Technology(Group)(中国)、etectrx(米国)、Check-Cap(イスラエル)、BodyCap(フランス)、Shangxian Minimal Invasive Inc(中国)などがあります。
目次
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKET SEGMENTATION & GEOGRAPHICAL SPREAD
1.3.2 INCLUSIONS & EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key sources of secondary data
2.1.1.2 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Objectives of primary research
2.1.2.2 Key data from primary sources
2.1.2.3 Insights from primary experts
2.1.3 MARKET SIZE ESTIMATION
2.1.3.1 Supply-side analysis
2.1.3.2 Bottom-up approach (demand-side analysis)
2.1.3.3 Top-down approach (parent market assessment)
2.2 DATA TRIANGULATION
2.3 STUDY ASSUMPTIONS
2.4 RISK ANALYSIS
2.5 RESEARCH LIMITATIONS
2.5.1 METHODOLOGY-RELATED LIMITATIONS
2.5.2 SCOPE-RELATED LIMITATIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 SMART PILLS MARKET OVERVIEW
4.2 NORTH AMERICA: SMART PILLS MARKET, BY APPLICATION AND COUNTRY, 2023
4.3 SMART PILLS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
4.4 SMART PILLS MARKET: REGIONAL MIX
4.5 SMART PILLS MARKET: DEVELOPED VS. EMERGING MARKETS
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Rising demand for non-invasive diagnostic monitoring devices
5.2.1.2 Technological advancements in capsule endoscopy
5.2.1.3 Increasing incidence of colon cancer
5.2.2 RESTRAINTS
5.2.2.1 High R&D costs for technological developments and advancements
5.2.2.2 Low accuracy and reliability of sensors and cameras in smart pills
5.2.3 OPPORTUNITIES
5.2.3.1 Innovations in sensor technologies and wireless communication
5.2.3.2 Rising need for rapid drug delivery and development
5.2.4 CHALLENGES
5.2.4.1 Increased patient privacy and data security concerns
5.2.4.2 Shortage of skilled healthcare professionals
5.3 INDUSTRY TRENDS
5.3.1 ADVANCEMENTS IN SENSOR TECHNOLOGIES
5.3.2 INTEGRATION WITH AI AND ML
5.3.3 INTEGRATION WITH WEARABLE DEVICES
5.4 TECHNOLOGY ANALYSIS
5.4.1 KEY TECHNOLOGIES
5.4.1.1 Wireless communication systems
5.4.1.2 Sensor technologies
5.4.1.3 Self-powered ingestible smart pills
5.4.1.4 Adaptive frame rate technologies
5.4.1.5 iMAG
5.4.1.6 AI and ML
5.4.2 COMPLEMENTARY TECHNOLOGIES
5.4.2.1 Robotic technologies
5.4.2.2 Data analytics
5.4.3 ADJACENT TECHNOLOGIES
5.4.3.1 IoT
5.4.3.2 Cloud computing
5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
5.6 PIPELINE ANALYSIS
5.7 PORTER'S FIVE FORCES ANALYSIS
5.7.1 INTENSITY OF COMPETITIVE RIVALRY
5.7.2 THREAT OF NEW ENTRANTS
5.7.3 THREAT OF SUBSTITUTES
5.7.4 BARGAINING POWER OF SUPPLIERS
5.7.5 BARGAINING POWER OF BUYERS
5.8 KEY STAKEHOLDERS & BUYING CRITERIA
5.8.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.8.2 KEY BUYING CRITERIA
5.9 ECOSYSTEM ANALYSIS
5.10 VALUE CHAIN ANALYSIS
5.11 TARIFF & REGULATORY ANALYSIS
5.11.1 TARIFF DATA ANALYSIS
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.11.3 REGULATORY LANDSCAPE
5.11.3.1 North America
5.11.3.1.1 US
5.11.3.2 Europe
5.11.3.3 Asia Pacific
5.11.3.3.1 Japan
5.11.3.3.2 China
5.11.3.3.3 India
5.12 PRICING ANALYSIS
5.12.1 AVERAGE SELLING PRICE OF SMART PILLS, BY KEY PLAYER, 2023
5.12.2 AVERAGE SELLING PRICE TREND FOR CAPSULE ENDOSCOPES, BY REGION, 2020-2023
5.13 CASE STUDY ANALYSIS
5.13.1 INCREASED IMAGING CAPABILITIES FOR PATIENTS WITH SMALL BOWEL ABNORMALITIES
5.13.2 DETECTION OF GASTRIC POLYP & ERYTHEMA THROUGH MAGNETICALLY CONTROLLED CAPSULE ENDOSCOPES
5.13.3 AI-ASSISTED CAPSULE ENDOSCOPY TO DETECT OBSCURE GASTROINTESTINAL BLEEDING IN HIGH-RISK CARDIAC PATIENTS
5.14 PATENT ANALYSIS
5.14.1 PATENT PUBLICATION TRENDS FOR SMART PILLS
5.14.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
5.14.3 LIST OF KEY PATENTS
5.15 KEY CONFERENCES & EVENTS, 2025-2026
5.16 UNMET NEEDS & END-USER EXPECTATIONS
5.16.1 UNMET NEEDS
5.16.2 END-USER EXPECTATIONS
5.17 TRADE ANALYSIS
5.18 INVESTMENT & FUNDING SCENARIO
5.19 BUSINESS MODEL ANALYSIS
5.19.1 DIRECT SALES TO HEALTHCARE PROVIDERS
5.19.2 SUBSCRIPTION-BASED SOFTWARE AND DATA ANALYTICS SERVICES
5.20 IMPACT OF AI/GEN AI ON SMART PILLS MARKET
5.20.1 KEY USE CASES
5.20.2 CASE STUDIES OF AI/GEN AI IMPLEMENTATION
5.20.2.1 CapsoCam SV-1 Versus PillCam SB3 to detect obscure gastrointestinal bleeding
5.20.2.2 AARDEX Group partnered with etectRx, Inc. to track medication-taking behaviors
5.20.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
5.20.3.1 AI in endoscopy
5.20.3.2 Wearable devices
5.20.3.3 Digital healthcare
5.20.3.4 Home healthcare
5.20.4 USER READINESS & IMPACT ASSESSMENT
5.20.4.1 User readiness
5.20.4.1.1 User A: Hospitals
5.20.4.1.2 User B: Diagnostic centers
5.20.4.2 Impact assessment
5.20.4.2.1 User A: Hospitals
5.20.4.2.1.1 Implementation
5.20.4.2.1.2 Impact
5.20.4.2.2 User B: Diagnostic centers
5.20.4.2.2.1 Implementation
5.20.4.2.2.2 Impact
6 SMART PILLS MARKET, BY TARGET AREA
6.1 INTRODUCTION
6.2 SMALL INTESTINE
6.2.1 COMPLEXITIES IN DIAGNOSIS AND MONITORING OF SMALL INTESTINE TO AID ADOPTION OF SMART PILLS
6.3 LARGE INTESTINE
6.3.1 INCREASING INCIDENCE OF COLORECTAL CANCER TO SUPPORT MARKET GROWTH
6.4 ESOPHAGUS
6.4.1 HIGH PREVALENCE OF GASTROESOPHAGEAL REFLUX DISEASE AND BARRETT'S ESOPHAGUS TO AUGMENT MARKET GROWTH
6.5 STOMACH
6.5.1 IMPROVED DIAGNOSTIC ACCURACY AND EFFECTIVE PROXIMAL EXAMINATION SCOPE OF GASTRIC DISEASES TO DRIVE MARKET
7 SMART PILLS MARKET, BY APPLICATION
7.1 INTRODUCTION
7.2 CAPSULE ENDOSCOPY
7.2.1 INCREASED ABILITY TO ASSESS GASTROINTESTINAL BLEEDING AND SMALL BOWEL TUMORS TO DRIVE MARKET
7.3 PATIENT MONITORING
7.3.1 NEED FOR STREAMLINED INTEGRATION OF INNOVATIVE SENSOR TECHNOLOGIES TO DRIVE MARKET
7.4 TARGETED DRUG DELIVERY
7.4.1 SITE-SPECIFIC DRUG DELIVERY TO MINIMIZE DRUG DOSAGE AND REDUCE HEALTHCARE COSTS
8 SMART PILLS MARKET, BY DISEASE INDICATION
8.1 INTRODUCTION
8.2 OCCULT GASTROINTESTINAL BLEEDING
8.2.1 IMPROVED DIAGNOSTIC ACCURACY TO FUEL UPTAKE OF SMART PILLS AS PATIENT-FRIENDLY ALTERNATIVE
8.3 CROHN'S DISEASE
8.3.1 TECHNOLOGICAL ADVANCEMENTS IN CAPSULE ENDOSCOPY TO BOOST ADOPTION OF SMART PILLS
8.4 CELIAC DISEASE
8.4.1 RISING INCIDENCE OF SMALL INTESTINE DISORDERS TO DRIVE MARKET
8.5 SMALL BOWEL TUMORS
8.5.1 GROWING DEMAND FOR NON-INVASIVE DIAGNOSTICS TO PROPEL MARKET GROWTH
8.6 OTHER DISEASE INDICATIONS
9 SMART PILLS MARKET, BY END USER
9.1 INTRODUCTION
9.2 HOSPITALS
9.2.1 INCREASING PREVALENCE OF INFLAMMATORY BOWEL DISEASE TO BOOST ADOPTION OF SMART PILLS IN HOSPITALS
9.3 DIAGNOSTIC CENTERS
9.3.1 BETTER PATIENT EXPERIENCE AND IMPROVED OPERATIONAL EFFICIENCY TO BOOST MARKET GROWTH
9.4 OUTPATIENT SETTINGS
9.4.1 NEED FOR ACCESSIBLE AND COST-EFFECTIVE CARE TO SPUR MARKET GROWTH
9.5 OTHER END USERS
10 SMART PILLS MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
10.2.2 US
10.2.2.1 US to dominate North American smart pills market during study period
10.2.3 CANADA
10.2.3.1 Rising incidence of IBD among geriatric population to propel market growth
10.3 EUROPE
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
10.3.2 GERMANY
10.3.2.1 Rising prevalence of Crohn's disease to aid market growth
10.3.3 UK
10.3.3.1 Increasing prevalence of bowel cancer and colitis to augment market growth
10.3.4 FRANCE
10.3.4.1 Favorable reimbursement coverage by government and third-party payers to aid market growth
10.3.5 ITALY
10.3.5.1 Growing adoption of capsule endoscopy for gastrointestinal diseases to propel market growth
10.3.6 SPAIN
10.3.6.1 Rising demand for non-invasive diagnostics to fuel uptake of smart pills
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
10.4.2 JAPAN
10.4.2.1 Increased prevalence of stomach cancer and favorable reimbursement scenario for capsule endoscopy to drive market
10.4.3 CHINA
10.4.3.1 Increasing geriatric population and rising incidence of gastric cancer to boost market growth
10.4.4 INDIA
10.4.4.1 Rising incidence of IBD and growing adoption of capsule endoscopy to support market growth
10.4.5 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
10.5.2 BRAZIL
10.5.2.1 Favorable government policies and presence of universal health coverage to aid market growth
10.5.3 MEXICO
10.5.3.1 Increased cancer awareness and favorable government initiatives to drive market
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST & AFRICA
10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
10.6.2 GCC COUNTRIES
10.6.2.1 Increased focus on healthcare infrastructure development and high R&D investment to support market growth
10.6.3 REST OF MIDDLE EAST & AFRICA
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN SMART PILLS MARKET
11.3 REVENUE ANALYSIS, 2019-2023
11.4 MARKET SHARE ANALYSIS, 2023
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
11.5.5.1 Company footprint
11.5.5.2 Region footprint
11.5.5.3 Application footprint
11.5.5.4 Target area footprint
11.5.5.5 Disease indication footprint
11.5.5.6 End-user footprint
11.5.5.7 Region footprint
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
11.6.5.1 Detailed list of key startups/SME players
11.6.5.2 Competitive benchmarking of key startups/SME players
11.7 COMPANY VALUATION & FINANCIAL METRICS
11.7.1 FINANCIAL METRICS
11.7.2 COMPANY VALUATION
11.8 BRAND/PRODUCT COMPARISON
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES, APPROVALS, AND ENHANCEMENTS
11.9.2 DEALS
11.9.3 OTHER DEVELOPMENTS
12 COMPANY PROFILES
12.1 KEY PLAYERS
12.1.1 MEDTRONIC
12.1.1.1 Business overview
12.1.1.2 Products/Services/Solutions offered
12.1.1.3 Recent developments
12.1.1.3.1 Product approvals & enhancements
12.1.1.3.2 Deals
12.1.1.4 MnM view
12.1.1.4.1 Right to win
12.1.1.4.2 Strategic choices
12.1.1.4.3 Weaknesses & competitive threats
12.1.2 OLYMPUS CORPORATION
12.1.2.1 Business overview
12.1.2.2 Products/Services/Solutions offered
12.1.2.3 Recent developments
12.1.2.3.1 Other developments
12.1.2.4 MnM view
12.1.2.4.1 Right to win
12.1.2.4.2 Strategic choices
12.1.2.4.3 Weaknesses & competitive threats
12.1.3 CAPSOVISION, INC.
12.1.3.1 Business overview
12.1.3.2 Products/Services/Solutions offered
12.1.3.3 Recent developments
12.1.3.3.1 Product approvals & enhancements
12.1.3.4 MnM view
12.1.3.4.1 Right to win
12.1.3.4.2 Strategic choices
12.1.3.4.3 Weaknesses & competitive threats
12.1.4 INTROMEDIC
12.1.4.1 Business overview
12.1.4.2 Products/Services/Solutions offered
12.1.4.3 MnM view
12.1.4.3.1 Right to win
12.1.4.3.2 Strategic choices
12.1.4.3.3 Weaknesses & competitive threats
12.1.5 JINSHAN SCIENCE & TECHNOLOGY
12.1.5.1 Business overview
12.1.5.2 Products/Services/Solutions offered
12.1.5.3 MnM view
12.1.5.3.1 Right to win
12.1.5.3.2 Strategic choices
12.1.5.3.3 Weaknesses & competitive threats
12.1.6 ANX ROBOTICS
12.1.6.1 Business overview
12.1.6.2 Products/Services/Solutions offered
12.1.6.3 Recent developments
12.1.6.3.1 Product launches, approvals, and enhancements
12.1.7 SHENZHEN JIFU MEDICAL TECHNOLOGY CO., LTD.
12.1.7.1 Business overview
12.1.7.2 Products/Services/Solutions offered
12.1.8 ETECTRX
12.1.8.1 Business overview
12.1.8.2 Products/Services/Solutions offered
12.1.8.3 Recent developments
12.1.8.3.1 Product enhancements
12.1.8.3.2 Deals
12.1.9 BODYCAP
12.1.9.1 Business overview
12.1.9.2 Products/Services/Solutions offered
12.1.9.3 Recent developments
12.1.9.3.1 Product launches
12.1.9.3.2 Deals
12.1.10 CHECK-CAP
12.1.10.1 Business overview
12.1.10.2 Products/Services/Solutions offered
12.1.10.3 Recent developments
12.1.10.3.1 Product approvals
12.1.10.3.2 Expansions
12.1.11 SHANGXIAN MINIMAL INVASIVE INC.
12.1.11.1 Business overview
12.1.11.2 Products/Services/Solutions offered
12.2 OTHER PLAYERS
12.2.1 VELOCE CORPORATION
12.2.2 BIOCAM
12.2.3 ENDIATX
12.2.4 RF CO., LTD.
12.2.5 CELERO SYSTEMS
12.2.6 BIORA THERAPEUTICS, INC.
12.2.7 INNURVATION
12.2.8 RANI THERAPEUTICS
12.2.9 MOTILIS MEDICA SA
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
